ClinicalTrials.gg

Program

camtarkibart

Also written as “611”, “Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)” and “611 300 mg Q2W”.

Its studies are mostly in Dermatitis, Atopic · Sinusitis · Pulmonary Disease, Chronic Obstructive, led by 3SBio.

Furthest: phase 3, since Dec 7, 202311 company-led studies, 5 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio115 open or runningphase 3since Dec 7, 2023Jul 16, 2020Sep 2027phase 3 · NCT07767253

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2020First study: phase 1 study in HealthyFirst studyNCT04527718 · 40 enrolled · United States
  2. Sep 9, 2022Phase 2 study in Dermatitis, AtopicNCT05544591 · 93 enrolled · China
  3. Nov 2, 2022Phase 2 study in Dermatitis, AtopicNCT05641558 · 24 enrolled · China
  4. Apr 25, 2023Phase 2 study in SinusitisNCT05865496 · 90 enrolled · China
  5. Oct 19, 2023Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06099652 · 142 enrolled · China
  6. Dec 7, 2023Phase 3 study in Dermatitis, AtopicNCT06173284 · 519 enrolled · China
  7. Mar 14, 2024Phase 2 study in Dermatitis, AtopicNCT06324812 · 128 enrolled · China
  8. Oct 9, 2024Phase 3 study in SinusitisNCT06639295 · 243 enrolled · China
  9. Jun 5, 20252 phase 3 studiesNCT07039669, NCT07042126
  10. Aug 7, 2026Phase 3 study in Dermatitis, AtopicNCT07767253 · 246 planned · China

Ahead

  1. Sep 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07767253
  2. Sep 2028Primary completion: phase 3 study in Lung DiseasesNCT07039669

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07767253Dermatitis, Atopic · China3RecruitingSep 2027246
NCT07042126Dermatitis, Atopic · China3RecruitingJun 30, 2026180
NCT07039669Lung Diseases · China3RecruitingSep 2028594
NCT06639295Sinusitis · China3Active, not recruitingDec 2025243
NCT06324812Dermatitis, Atopic · China2CompletedMay 25, 2026128
NCT06173284Dermatitis, Atopic · China3CompletedSep 26, 2025519
NCT06099652Pulmonary Disease, Chronic Obstructive · China2CompletedApr 15, 2025142
NCT05865496Sinusitis · China2Active, not recruitingMay 31, 202490
NCT05641558Dermatitis, Atopic · China2CompletedOct 21, 202224
NCT05544591Dermatitis, Atopic · China2CompletedJul 10, 202393
NCT04527718Healthy · United States1CompletedAug 13, 202140

How it is read

Names in the registry

  • “611”, 8 entries
  • “Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)”, 1 entry
  • “611 300 mg Q2W”, 1 entry
  • “611 450 mg Q2W”, 1 entry
  • “611 Q2W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.